Lexaria Bioscience Announces 1-for-15 Reverse Stock Split to Regain NASDAQ Compliance

summarizeSummary

Lexaria Bioscience Corp. announced a 1-for-15 reverse stock split, effective August 3, 2026, primarily to regain compliance with NASDAQ's minimum bid price requirement and stabilize its stock conditions.

check_boxKey Events · Corporate Governance and Compliance · LEXX

• 1-for-15 Reverse Stock Split

  The company will effect a 1-for-15 reverse stock split of its authorized and outstanding common stock, effective August 3, 2026.

• NASDAQ Compliance Goal

  The primary reason for the split is to increase the per-share market price to regain compliance with the NASDAQ Capital Market's minimum $1.00 bid price rule, following previous disclosures of delisting risk.

• Capitalization Adjustment

  Authorized shares will decrease from 220,000,000 to 14,666,667, and outstanding shares will reduce from 24,787,446 to approximately 1,652,518. Fractional shares will be rounded up.

• No Shareholder Approval Required

  The Board of Directors approved the split under Nevada law, which does not require shareholder approval for this type of proportional reduction.

auto_awesomeAnalysis · LEXX · Life Sciences

This reverse stock split is a critical move for Lexaria Bioscience, directly addressing the NASDAQ minimum bid price requirement to avoid delisting. The company's recent 10-Q filing highlighted a going concern warning and delisting risk, making this action a necessary step for its continued survival on a major exchange. While it resolves an immediate compliance issue, it does not fundamentally alter the underlying business challenges or the company's cash runway, which was noted to extend only into early 2027. The market typically views reverse splits negatively as they often signal distress, but for Lexaria, it's a crucial measure to maintain market access.